ЛИТЕРАТУРА

  1. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-372.
  2. Rosenson, R.S., and Tangney, C.C.. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279: 1643-1650.
  3. Davignon J., Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 1999; 10: 543-559.
  4. Н.А.Грацианский. Статины как противовоспалительные средства. Кардиология 2001, том 12, стр. 14-26.
  5. Грацианский Н.А. Нестабильная стенокардия - острый коронарный синдром. III. Предупреждение обострений ишемической болезни сердца. Статины и антибиотики. Кардиология 1997; №11: 4-17.
  6. Schwartz G. G., Olssln A. G., Ezekovitz M. D., et al. Effect of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-1718.
  7. Danchin N., Grenier O., Thomas D., et al. Differences in secondary prevenyion medications used after acute myocardial infarction or unstable angina: results from the nation-wide French PREVENIR survey (abstract). Eur Heart J. 2000, 21, Suppl., p. 370.
  8. Fonarow G.C., Gawlinski A., Moughrabi S., et all. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Amer J Cardiol 2001; 87: 819-822.
  9. Kinlay S., Rafai N., Libby P., et al. Effect of atorvastatin on C-reactive protein in patients with acute coronary syndromes: a substudy of the MIRACL trial (abstract). J Amer Coll Cardiol 2002,
  10. Dupuis J., Tardif J. C., Cernacek P., et al. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE trial. Circulation1999; 99: 3227-3233.
  11. Ваулин Н.А., Грацианский Н.А., Славина Н.Н., Аверков О.В. Нестабильная стенокардия: влияние правастатина на липиды и агрегацию тромбоцитов. Кардиология 1999. 39; 8: 42-52.
  12. Ваулин Н. А., Грацианский Н. А. Нестабильная стенокардия. Маркеры воспаления при краткосрочном раннем применении правастатина. Кардиология 2001; 11: 4-10.
  13. Vaughan C.J., Gotto A.M., Jr., Basson C.T. The Evolving Role of Statins in the Management of Atherosclerosis. J Am Coll Cardiol 2000; 35:1–10.
  14. Габбасов З. А., Попов Е. Г., Гаврилов И. Ю. и др. Новый высокочувствительный метод анализа агрегации тромбоцитов. Лаб. дело 1989, 10: 15 – 18.
  15. Габбасов З. А., Попов Е. Г., Гаврилов И. Ю. И др. Новый методический подход к исследованию агрегации тромбоцитов in vitro. Бюл экспер биол 1989, 10: 437 – 439.
  16. Cattaneo M., Akkawat B., Lecchi A., et al. Ticlopidine selectively inhibits human platelet responses to adenosine diphosphate. Thromb Haemost 1991; 66: 694-699.
  17. Ноева Е. А. Динамика спектра липопротеидов и аполипопротеинов в плазме крови у больных инфарктом миокарда и нестабильной стенокардией, их связь с течением заболевания. Автореферат кандидатской диссертации – М., 1985.
  18. Аверков О. В. Сравнительное изучение клинической эффективности и влияния на показатели фибринолиза гепарина и аспирина у больных нестабильной стенокардией. Автореферат кандидатской диссертации. – М., 1993. Mayer J., Eller T. Brauer P., et al. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. JAMA 1998; 279(20):1 659-661.
  19. Beigel Y., Fuchs J., Snir M., et al. Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorreologic parameters, platelet activity, and red blood cell morphology. Ann Hematol 1992, 64: 196-201.
  20. Notarbartolo A., Davi G., Averna M., et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hyperholesterolemia. Arteriosc Thromb Vasc Biol 1995; 15: 247-251.
  21. Dujovne C.A., Harris W. S., Altman R., et al. Effect of atorvastatin on hemorheoologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. Am J Cardiol 2000; 85: 350-353.
  22. Osamah H., Mira R., Sorina S. et al. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Pharmacol 1997; 44: 77-83.
  23. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. New Engl J Med 2001; 345: 494-502.
  24. Trip M. D., Cats V. M., van Capelle F. J. L., et al. Platelet hyper-reactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 1549-1554. Mischke R., Anders C., Winkler R., et al. Effects of treatment with atorvastatin on the activation of thrombocytes (abstract). Eur Heart J. 2001, 22: 272. McEver R.P. Properties of GMP-140, an inducible granule membrane protein of platelets and endothelium. Blood Cells 1990; 16: 73-80.
  25. Johnston G. I., Kurosky A., McEver R. P. Structural and biosynthetic studies of the granule membrane protein, gmp-140, from human platelets and endothelial cells. J Biol Chem 1989; 264: 1816-1823.
  26. Hsu-Lin S. C., Berman C. L., Furie B. C., et al. A platelet membrane protein expressed during platelet activation and secretion. Studies using monoclonal antibody specific for thrombin-activated platelets. J Biol Chem 1984; 259: 9121-9126.
  27. Le Quan Sang K. H., Levenson J., Megnien J. L., et al. Platelet cytosolic Ca and membrane dynamics in patients with primary hypercholesterolemia: effects of pravastatin. Arterioscler Thromb Vasc Biol 1995; 15: 759-764.
  28. Liuzzo G., Biasucci L. M., Gallimore J. R., et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331: 417-424.
  29. Morrow D.A., Rifai N., Antman E.M., et al. C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy. JACC Vol. 31, No. 7, June 1998:1460-1465.
  30. Ridker P.M., Cushman M., Stampfer M. J., et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973-979.
  31. Ridker P.M., Buring J. E., Shih J., et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-733.
  32. Koenig W., Sund M., Frohlich M., et al. C-Reactive Protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from MONICA (Monitoring Trends and Determinants in Cardiovascular Desease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99:237-242.
  33. Biasucci L. M., Vielli A., Liuzzo G., et al. Increasing levels of (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999; 99: 2079-2084.
  34. Lindmark E., Diderholm E., Wallentin L., et al. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease. effects of an early invasive or noninvasive strategy. JAMA, 2001; 286: 2107-2113.
  35. Ridker P M., Rafai N., Stampfer M. J., et al. Plasma concentration of interleikin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-1772.
  36. Lagrand W. K., Visser C. A., Hermens W. T., et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999; 100: 96-102.
  37. Reynolds G. D., Vance R. P. C-reactive protein immunohistochemical localisation in normal and atherosclerotic human aortas. Arch Pathol Lab Med 1987; 111: 265-269.
  38. Torzewski M, Rist C., Mortensen R. F., et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arteroiscler Thromb Vasc Biol 2000; 20:2094-2098.
  39. vPasceri V., Willerson J.T., Yeh E.T. Direct proinflammatiry effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-2099.
  40. Pasceri V., Chang J., Willerson J.T., et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-aterosclerosis drugs. Circulation 2001; 103: 2531-2534.
  41. Nakagomi A, Freedman S. B., Geczy C. L. Interferon-gamma and lipopolysaccaride potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, hormone replacement treatment. Circulation 2000; 101: 1785-1791.
  42. Salbach P., Lang S., Kuchler D., Dugi K., Kreuzer J. Short term treatment with atorvastatin: decrease of inflammatory markers and binding activity of NF-kappaB in patients with hypercholesterolaemia (abstr.). Eur Heart J 2001; 22, Abstr Suppl:.644.
  43. Hughes A.D. The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering. J Hum Hypertens 1996; 10: 387-390.